FQ
CTMX icon

First Quadrant’s CytomX Therapeutics CTMX Stock Holding History

First Quadrant’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,100
Closed -$16K – 515
2021
Q3 		$16K Sell
3,100
-40,100
-93% -$215K ﹤0.01% 500
2021
Q2 		$273K Sell
43,200
-43,600
-50% -$340K 0.03% 311
2021
Q1 		$671K Buy
86,800
+35,601
+70% +$282K 0.07% 221
2020
Q4 		$335K Sell
51,199
-8,201
-14% -$58.6K 0.03% 302
2020
Q3 		$395K Sell
59,400
-11,159
-16% -$82.8K 0.05% 247
2020
Q2 		$588K Buy
+70,559
New +$655K 0.08% 240
2018
Q3 		– Sell
-9,748
Closed -$223K – 849
2018
Q2 		$223K Sell
9,748
-5,718
-37% -$146K ﹤0.01% 577
2018
Q1 		$440K Sell
15,466
-3,482
-18% -$99.4K 0.01% 502
2017
Q4 		$400K Buy
18,948
+10,437
+123% +$216K 0.01% 583
2017
Q3 		$155K Sell
8,511
-1,835
-18% -$28.6K ﹤0.01% 747
2017
Q2 		$160K Buy
+10,346
New +$156K ﹤0.01% 712

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Quadrant's CTMX Position: Q4 2021 in Review

First Quadrant sold out of CytomX Therapeutics (CTMX) in Q4 2021, closing a stake of 3,100 shares — an estimated $16K sold.

First Quadrant first reported a position in CTMX in Q2 2017 and held it in 11 quarters. The position peaked at $671K in Q1 2021. 110 funds tracked by Wall St. Rank hold CTMX as of Q4 2021.

  • First Quadrant reported no remaining CytomX Therapeutics position as of Q4 2021 after selling out during the quarter.
  • First Quadrant sold 3,100 CytomX Therapeutics shares in Q4 2021, an estimated $16K.
  • First Quadrant first reported a position in CytomX Therapeutics in Q2 2017 and held it in 11 quarters.
  • First Quadrant's CytomX Therapeutics position peaked at $671K in Q1 2021.
  • 110 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2021.

Based on First Quadrant's 13F filing for Q4 2021, filed 27 Jan 2022.